The Transformation of Clinical Trial Strategies in the Era of Decentralized and Hybrid Opportunities
The Transformation of Clinical Trial Strategies in the Era of Decentralized and Hybrid Opportunities
Sponsored by:
Sponsored by:
More from Clinical Trials
• By
CMO Shreeram Aradhye talks to Scrip about the promise shown by ianalumab, remibrutinib and a next-generation CAR-T for immunological disorders.
• By
A Phase II trial to develop a second NaV1.8 pain signal inhibitor for acute pain has failed and the US FDA has given a thumbs down on Journavx’s path to broader use in peripheral neuropathic pain.
• By
Cardiff Oncology is open to going it alone, a partnership and even an exit as the San Diego, CA-based firm tries to push its PLK1 inhibitor through late-stage development.
• By
Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.
More from R&D
Sponsored by:
Learn how advances in vaccine adjuvants are shaping the future of global health and driving more effective immunization strategies
Sponsored by:
Learn how advances in vaccine adjuvants are shaping the future of global health and driving more effective immunization strategies
Sponsored by:
Insights from Novotech on Evolving Trends Impacting Global Clinical Development
Sponsored by:
Lonza is addressing the growing global demand for biologics by utilizing its expert teams and the advanced capabilities of its newly acquired large-scale manufacturing site in Vacaville, California. Joanna McCafferty, Director of Commercial Development, shares more in this brief video. Ask ChatG